We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioprogress | LSE:BPRG | London | Ordinary Share | GB0032681628 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 50.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:3424C BioProgress PLC 17 August 2007 For Immediate Release 17 August 2007 BioProgress plc ('BioProgress' or the 'Company') AIM Rule 26 London, UK, 17 August 2007: BioProgress (AIM: BPRG), the specialty pharma and healthcare company announces that information required by AIM Rule 26 (Company Information Disclosure) is available on the Company's investor relations section of the website located at www.bioprogress.com. For further information: BioProgress Plc + 44 (0) 20 7098 9881 Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000 Rebecca Skye Dietrich Mark Court About BioProgress BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the United States as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL TM polymer technology. For further information please go to www.bioprogress.com Forward-Looking Information This announcement may contain forward-looking statements that reflect the current views of BioProgress plc's management with respect to future events. Forward-looking statements are based on current plans, estimates and projections. You should consider them with caution. Such statements are subject to risks and uncertainties, most of which are difficult to predict and are generally beyond BioProgress plc's control. Detailed information about factors pertinent to the business of the Company that could cause actual results to differ is set forth in BioProgress plc's public reports and announcements, which are published by the Regulatory News Service (RNS), the company news service of the London Stock Exchange and on the Company's Web site (http:// www.bioprogress.com). If these or other risks and uncertainties materialize, or if the assumptions underlying any of these statements prove incorrect, BioProgress plc's actual results may be materially different from those expressed or implied by such statements. The Company can offer no assurance that its expectations or targets will be achieved. BioProgress plc does not assume any obligation (and expressly disclaims any such obligation) to update forward-looking statements to take new information or future events into account or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities, or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. This information is provided by RNS The company news service from the London Stock Exchange END MSCBBGDIUSBGGRR
1 Year Bioprogress Chart |
1 Month Bioprogress Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions